NasdaqGM - Nasdaq Real Time Price • USD
Adagene Inc. (ADAG)
At close: May 14 at 4:00 PM EDT
Pre-Market: 8:36 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 2 |
| Avg. Estimate | -0.42 | -0.42 | -1.66 | -0.9 |
| Low Estimate | -0.42 | -0.42 | -1.66 | -0.92 |
| High Estimate | -0.42 | -0.42 | -1.66 | -0.88 |
| Year Ago EPS | -- | -- | -1.28 | -1.66 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 2 |
| Avg. Estimate | -- | -- | 18.11M | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | 9.29M | 18.11M |
| Sales Growth (year/est) | -- | -- | 94.90% | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | |||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -0.93 |
| EPS Actual | -- | -- | -- | -0.87 |
| Difference | -- | -- | -- | 0.06 |
| Surprise % | -- | -- | -- | 6.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | -0.42 | -0.42 | -1.66 | -0.9 |
| 7 Days Ago | -0.42 | -0.42 | -1.66 | -0.9 |
| 30 Days Ago | -0.42 | -0.42 | -1.66 | -0.9 |
| 60 Days Ago | -0.42 | -0.42 | -1.66 | -1.37 |
| 90 Days Ago | -0.42 | -0.82 | -1.15 | -2.01 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ADAG | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 8.40% |
| Next Qtr. | -- | -- | -- | 11.90% |
| Current Year | -29.70% | -- | -- | 5.60% |
| Next Year | 45.80% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 11.05% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/4/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/1/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 4/21/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/29/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/21/2023 |
| Maintains | Morgan Stanley: Overweight | 1/24/2023 |
Related Tickers
AVBP ArriVent BioPharma, Inc.
18.46
+2.96%
CNTB Connect Biopharma Holdings Limited
1.9500
+39.29%
CNTA Centessa Pharmaceuticals plc
9.04
+2.38%
SNSE Sensei Biotherapeutics, Inc.
1.5100
-3.82%
BCAB BioAtla, Inc.
2.6100
-1.14%
IPHA Innate Pharma S.A.
2.6400
+6.88%
THRD Third Harmonic Bio, Inc.
12.91
+7.05%
FNCH Finch Therapeutics Group, Inc.
1.9400
+3.19%
RKVTF RAKOVINA THERAPEUTICS INC
0.0600
0.00%
ANRO Alto Neuroscience, Inc.
14.16
+0.50%